|

Tranexamic Acid Use for Bleeding Prevention in the Surgical Treatment of Metastatic Spinal Tumor in Lung Cancer Patients

RECRUITINGPhase 1/2Sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University
Actively Recruiting
PhasePhase 1/2
SponsorSecond Affiliated Hospital, School of Medicine, Zhejiang University
Started2023-12-01
Est. completion2026-01-01
Eligibility
Age10 Years – 80 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06023212

Summary

Massive blood loss occurs in metastatic spinal tumor resection and may cause severe complications. The objective of this study is to investigate whether the use of tranexamic acid will reduce perioperative and postoperative bleeding when compared to those without use of tranexamic acid.

Eligibility

Age: 10 Years – 80 YearsHealthy volunteers accepted
Inclusion Criteria:

* Diagnosed as metastatic carcinoma of the thoracolumbar spine
* solitary neoplasm involve only one segment of spine
* patients underwent separation surgery

Exclusion Criteria:

* coagulation function was abnormal preoperatively
* patients are allergic to tranexamic acid
* neoplasm involve more than one segment of spine
* patients with rich blood supply who need embolization

Conditions3

CancerLung CancerMetastasis Spinal Tumor

Browse More Trials

Cancer trialsLung Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.